Gene expression analyses in X-linked myotubular myopathy

Neurology

Volumn 65, Issue 5, 2005, Pages 732-737

  Noguchi, Satoru ^a   Fujita, M ^b   Murayama, K ^b   Kurokawa, R ^b   Nishino, I ^b  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; MYOTUBULARIN; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 PHOSPHATE; PROTEIN; SCLEROPROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CENTRONUCLEAR MYOPATHY; CLINICAL ARTICLE; CYTOARCHITECTURE; CYTOSKELETON; DNA MICROARRAY; EXTRACELLULAR MATRIX; GENE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; HYPOPLASIA; INFANT; KNOCKOUT MOUSE; MTM1 GENE; MUSCLE; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE HYPOTONIA; MUSCLE WEAKNESS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SKELETAL MUSCLE; TRANSCRIPTION REGULATION; X CHROMOSOME LINKED DISORDER;

EID: 24644440937     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000174625.67484.4d     Document Type: Article

References (32)

1. Fardeau M, Tome FMS. Congenital myopathies. In: Engel AG, Franzini-Armstrong C, eds. Myology, 2nd Ed. New York: McGraw-Hill, 1994;1487-1532.
2. Wallgren-Pettersson C, Clarke A, Samson F, et al. The myotubular myopathies: differential diagnosis of the X linked recessive, autosomal dominant, and autosomal recessive forms and present state of DNA studies. J Med Genet 1995;32:673-679.
3. Laporte J, Hu LJ, Kretz C, et al. A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. Nat Genet 1996;13:175-182.
4. Laporte J, Biancalana V, Tanner SM, et al. MTM1 mutations in X-linked myotubular myopathy. Hum Mutat 2000;15:393-409.
5. Herman GE, Kopacz K, Zhao W, Mills PL, Metzenberg A, Das S. Characterization of mutations in fifty North American patients with X-linked myotubular myopathy. Hum Mutat 2002;19:114-121.
6. Biancalana V, Caron O, Gallati S, et al. Characterisation of mutations in 77 patients with X-linked myotubular myopathy, including a family with a very mild phenotype. Hum Genet 2003;112:135-142.
7. Nishino I, Minami N, Kobayashi O, et al. MTM1 gene mutations in Japanese patients with the severe infantile form of myotubular myopathy. Neuromuscul Disord 1998;8:453-458.
8. Mandel JL, Laporte J, Buj-Bello A, Sewry C, Wallgren-Pettersson C. In: Karpati G, ed. Structural and molecular basis of skeletal muscle diseases. Basel: ISN Neuropath Press, 2002;124-129.
9. Spiro AJ, Shy GM, Gonatas NK. Myotubular myopathy. Persistence of fetal muscle in an adolescent boy. Arch Neurol 1966;14:1-14.
10. Buj-Bello A, Laugel V, Messaddeq N, et al. The lipid phosphatase myotubularin is essential for skeletal muscle maintenance but not for myogenesis in mice. Proc Natl Acad Sci USA 2002;99:15060-15065.
11. Blondeau F, Laporte J, Bodin S, Superti-Furga G, Payrastre B, Mandel JL. Myotubularin, a phosphatase deficient in myotubular myopathy, acts on phosphatidylinositol 3-kinase and phosphatidylinositol 3-phosphate pathway. Hum Mol Genet 2000;9:2223-2229.
12. Schaletzky J, Dove SK, Short B, Lorenzo O, Clague MJ, Barr FA. Phosphatidylinositol-5-phosphate activation and conserved substrate specificity of the myotubularin phosphatilinositol 3-phosphatases. Curr Biol 2003;13:504-509.
13. Laporte J, Blondeau F, Gansmuller A, Lutz Y, Vonesch JL, Mandel JL. The PtdIns3P phosphatase myotubularin is a cytoplasmic protein that also localizes to Rac1-inducible plasma membrane ruffles. J Cell Sci 2002;115:3105-3317.
14. Nandurkar HH, Layton M, Laporte J, et al. Identification of myotubularin as the lipid phosphatase catalytic subunit associated with the 3-phosphatase adapter protein, 3-PAP. Proc Natl Acad Sci USA 2003; 100:8660-8665.
15. Leevers SJ, Vanhaesebroeck B, Waterfield MD. Signaling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol 1999;11:219-225.
16. Rameh LE, Cantley LC. The role of phospahoinositide 3-kinase lipid products in cell function. J Biol Chem 1999;274:8347-8350.
17. Tsujita K, Itoh T, Ijuin T, et al. Myotubularin regulates the function of the late endosome through the gram domain-phosphatidylinositol 3,5-bisphosphate interaction. J Biol Chem 2004;279:13817-13824.
18. Chen YW, Zhao P, Borup R, Hoffman EP. Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathology. J Cell Biol 2000;151:1321-1336.
19. Bakay M, Zhao P, Chen J, Hoffman EP. A web accessible complete transcriptome of normal human and DMD muscle. Neuromuscul Disord 2002;12:S125-S141.
20. Campanaro S, Romualdi C, Fanin M, et al. Gene expression profiling in dystrophinopathies using dedicated muscle microarray. Hum Mol Genet 2002;11:3283-3289.
21. Noguchi S, Tsukahara T, Fujita M, et al. cDNA microarray analysis of individual Duchenne muscular dystrophy patients. Hum Mol Genet 2003;12:595-600.
22. Sanoudou D, Haslett JN, Kho AT, et al. Expression profiling reveals altered satellite cell numbers and glycolytic enzyme transcription in nemaline myopathy muscle. Proc Natl Acad Sci USA 2003;100:4666-4671.
23. Tsai T-C, Horinouchi H, Noguchi S, et al. Characterization of MTM1 mutations in 31 Japanese families with myotubular myopathy, including a patient carrying 240 kb deletion in Xq28 without male hypogenitalism. Neuromuscul Disord 2005;15:245-252.
24. Hayashi YK, Ogawa M, Tagawa K, et al. Selective deficiency of a-dystroglycan in Fukuyama-type congenital muscular dystrophy. Neurology 2001;57:115-121.
25. Hagg PM Hagg PO, Peltonen S, Autio-Harmainen H, Pihlajaniemi T. Location of type XV collagen in human tissues and its accumulation in the interstitial matrix of the fibrotic kidney. Am J Pathol 1997;150: 2075-2086.
26. Sandri M, Sandri C, Gilbert A, et al. Foxo transcriptional factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004;117:399-412.
27. Stitt TN, Drujan D, Clarke BA, et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004;14:395-403.
28. Cai D, Frantz JD, Tawa Jr, NE, et al. IKKβ/NF-κB activation causes severe muscle wasting in mice. Cell 2004;119:285-298.
29. Kamei Y, Miura S, Suzuki M, et al. Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J Biol Chem 2004;279:41114-41123.
30. Kreis T, Vale R, eds. Guidebook to the cytoskeletal and motor proteins, 2nd ed. New York: Oxford University Press, 1999.
31. Glass DJ. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat Cell Biol 2003;5:87-90.
32. Takenawa T, Miki H. WASP and WAVE family proteins: key molecules for rapid rearrangement of cortical actin filaments and cell movement. J Cell Sci 2001;114:1801-1809.